spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Hana Biosciences 

 HSMN NewsFeed - 16 Jul 2018
enGene Appoints Veteran Life Sciences Executive Jason D. Hanson as Chief Executive Officer and President
Biopharmaceuticals Drug Delivery Personnel
 HSMN NewsFeed - 4 Oct 2011
Galena Biopharma Hires Hana B. Moran as Vice President, Regulatory Affairs and Compliance
Biopharmaceuticals Personnel
 HSMN NewsFeed - 31 Mar 2011
RXi Pharmaceuticals Aggressively Moves into Late-Stage Clinical Development with the Agreement to Acquire Apthera, Inc.
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 15 Feb 2011
Aeolus Pharmaceuticals Announces Appointment of Russell L. Skibsted as Senior Vice President and Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 Dec 2009
Hana Biosciences Appoints Howard Furst, M.D., M.B.A., to Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 7 Dec 2009
Hana Biosciences Announces Positive Data From Pivotal rALLy Clinical Trial of Marqibo(R) in Acute Lymphoblastic Leukemia at 51st American Society of Hematology Annual Meeting
Biopharmaceuticals Drug Delivery Oncology
 HSMN NewsFeed - 12 Jan 2009
Hana Biosciences Appoints Thomas J. Tarlow as Vice President, Regulatory Affairs and Quality
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 Jul 2008
Hana Biosciences' Marqibo Receives Orphan Designation From European Commission for the Treatment of Adult Acute Lymphoblastic Leukemia
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 30 Jun 2008
Hana Biosciences Receives U.S. Orphan Drug Designation for Marqibo for the Treatment of Metastatic Uveal Melanoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 24 Apr 2008
Hana Biosciences Appoints Anne E. Hagey, M.D., Vice President and Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 30 Mar 2008
Tekmira Pharmaceuticals and Protiva Biotherapeutics Announce Business Combination to Create Global Leader in RNAi Delivery and Therapeutics
Biopharmaceuticals
 HSMN NewsFeed - 23 Jan 2008
Hana Biosciences Announces Changes in Senior Management
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 30 Aug 2007
Hana Biosciences Appoints S. Michael Imperiale, Jr., M.D., as Vice President, Clinical Research Operations
Biopharmaceuticals Personnel
 HSMN NewsFeed - 24 Aug 2007
Hana Biosciences Appoints Dr. Steven R. Deitcher President and CEO
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 22 Aug 2007
Hana Biosciences Receives Fast Track Designation for Marqibo for the Treatment of Relapsed Acute Lymphoblastic Leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 1 Aug 2007
NovaDel Announces Sublicense Agreement for Zensana(TM)
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 1 Aug 2007
Hana Biosciences Licenses North American Commercial Rights for Zensana(TM) to Par Pharmaceutical in a $50 Million Deal
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 29 May 2007
SuperGen Names Gregory Berk, M.D., Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 May 2007
Hana Biosciences Announces Vice President Appointment in Regulatory Affairs and Quality Assurance
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 May 2007
Hana Biosciences Announces Appointment of Steven R. Deitcher, M.D. as Executive Vice President and Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 Mar 2007
NovaDel's European Formulation of Ondansetron Targeted for U.S. Zensana(TM)
Biopharmaceuticals
 HSMN NewsFeed - 28 Feb 2007
Hana Biosciences Appoints Lyn Wiesinger to Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 26 Feb 2007
INEX Provides Timeline for Completing Spin-out of Tekmira Pharmaceuticals Corporation
Biopharmaceuticals
 HSMN NewsFeed - 20 Feb 2007
NovaDel Comments on Delay in Zensana(TM) Launch, as Announced by Hana BioSciences
Biopharmaceuticals
 HSMN NewsFeed - 20 Feb 2007
Hana Biosciences Reports Likely Delay in Launch of Zensana(TM)
Biopharmaceuticals
 HSMN NewsFeed - 16 Jan 2007
Hana Biosciences Receives Orphan Drug Designation for Marqibo(R) (Vincristine Sulfate Liposomes Injection) for the Treatment of Acute Lymphoblastic Leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 20 Dec 2006
Hana Biosciences Announces Filing of a Special Protocol Assessment (SPA) for Marqibo(R) (Vincristine Sulfate Liposomes Injection) in Relapsed Acute Lymphoblastic Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Oct 2006
Hana Biosciences Licenses Drug Candidate for the Prevention and Treatment of EGFR Inhibitor-Associated Skin Rash
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 30 Aug 2006
FDA Accepts for Review NDA Filing for Zensana(TM) (Ondansetron HCI) Oral Spray
Biopharmaceuticals FDA
 HSMN NewsFeed - 5 Jul 2006
NovaDel Announces Filing of NDA for the Zensana(TM) (Ondansetron HCl) Oral Spray
Biopharmaceuticals Drug Delivery Oncology
 HSMN NewsFeed - 9 Jun 2006
Hana Biosciences Receives Orphan Drug Designation for Ropidoxuridine (IPdR), for the Treatment of Malignant Glioma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 22 May 2006
Hana Biosciences Receives Orphan Drug Designation for Talotrexin (PT-523), For the Treatment of Acute Lymphoblastic Leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 8 May 2006
Hana Biosciences Completes Licensing of Three Targeted Cancer Drug Candidates from Inex Pharmaceuticals
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 31 Mar 2006
Hana Biosciences Initiates Talotrexin Phase II Clinical Trials in Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Mar 2006
Hana Biosciences to License Three Targeted Cancer Drug Candidates from Inex Pharmaceuticals
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 17 Mar 2006
Inex Pharmaceuticals Licenses Three Targeted Chemotherapy Products to Hana Biosciences
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 9 Mar 2006
Hana Biosciences Successfully Completes Pivotal Trials of Zensana(TM), First Proprietary Ondansetron Oral Spray for Chemotherapy-Induced Nausea and Vomiting
Biopharmaceuticals
 HSMN NewsFeed - 9 Jan 2006
Hana Biosciences Announces Positive Results of Initial Registration Trial with Zensana(TM), First Ondansetron Oral Spray for Chemotherapy-Induced Nausea and Vomiting
Biopharmaceuticals
Return to NewsFeed  

 Additional items found! 12

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 12 additional stories matching:
Hana Biosciences
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.